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Despite major advances in the treatment of metastatic colorectal cancer
(mCRC), the survival rate remains very poor. This study aims at exploring
the prognostic value of RAS-mutant allele fraction (MAF) in plasma in
mCRC. Forty-seven plasma samples from 37 RAS-mutated patients with
nonresectable metastases were tested for RAS in circulating tumor DNA
using BEAMing before first- and/or second-line treatment. RAS MAF was
correlated with several clinical parameters (number of metastatic sites, hep-
atic volume, carcinoembryonic antigen, CA19-9 levels, primary site location,
and treatment line) and clinical outcome [progression-free survival (PFS) and
overall survival (OS)]. An independent cohort of 32 patients from the
CAPRI-GOIM trial was assessed for clinical outcome based on plasma base-
line MAF. RAS MAF analysis at baseline revealed a significant correlation
with longer OS [Hazard ratios (HR) = 3.514; P = 0.00066]. Patients with
lower MAF also showed a tendency to longer PFS, although not statistically
significant. Multivariate analysis showed RAS MAFs as an independent
prognostic factor in both OS (HR = 2.73; P = 0.006) and first-line PFS
(HR = 3.74; P = 0.049). Tumor response to treatment in patients with higher
MAF was progression disease (P = 0.007). Patients with low MAFs at base-
line in the CAPRI-GOIM group also showed better OS [HR = 3.84; 95%
confidence intervals (CI) 1.5–9.6; P = 0.004] and better PFS (HR = 2.5; 95%
CI: 1.07–5.62; P = 0.033). This minimally invasive test may help in adding an
independent factor to better estimate outcomes before initiating treatment.
Further prospective studies using MAF as a stratification factor could fur-
ther validate its utility in clinical practice.
Abbreviations
CEA, carcinoembryonic antigen; cfDNA, circulating free DNA; ctDNA, circulating tumor DNA; HR, hazard ratio; MAF, mutant allele fraction;
mCRC, metastatic colorectal cancer; OS, overall survival; PFS, progression-free survival.
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1. Introduction
The past two decades have witnessed significant pro-
gress in the treatment of metastatic colorectal cancer
(mCRC) partly due to a better selection of therapy
based on the tumor RAS mutation status. Nonethe-
less, the 5-year survival rate in mCRC patients remains
poor (Siegel et al., 2017). The large variability in sur-
vival shows that current routine prognostic evaluation
of mCRC is insufficient and needs to be improved, for
both resectable and nonresectable metastases. The
development of reliable prognostic biomarkers is an
increasingly pertinent tool in this setting.
In mCRC, the detection of circulating tumor DNA
(ctDNA) is an emerging alternative to detect muta-
tions, thus avoiding biopsies from primary or meta-
static sites. We and others previously reported ~ 90%
concordance of RAS-mutant status in paired plasma
and tissue samples, as well as its predictive value in
plasma for anti-EGFR therapy response (Bettegowda
et al., 2014; Grasselli et al., 2017; Siravegna et al.,
2015). Mutant allele fractions (MAFs) are a measure
of the percentage of mutant alleles within the totality
of alleles in any given sample. MAF estimations of dri-
ver genes have shown important clinical implications
in various settings. In a retrospective analysis of the
CRYSTAL trial (Van Cutsem et al., 2011), mCRC
patients with tumor RAS MAFs between 0.1% and
< 5% were more likely to benefit from the addition of
cetuximab to FOLFIRI. Likewise, resistance to anti-
EGFR therapies in mCRC with KRAS MAFs < 1%
(Azuara et al., 2016; Laurent-Puig et al., 2015) and
longer benefit with tyrosine kinase inhibitor therapy
were associated with higher MAFs in EGFR-mutated
lung cancer patients (Ono et al., 2014; Zhou et al.,
2011).
The potential prognostic value of plasma MAFs in
mCRC has not been well established yet. Interestingly,
we and others have observed that RAS MAF showed
a trend to lower overall survival (OS) when plasma
levels were above a cutoff of 10% and 1%, respec-
tively, although the population was heterogeneous in
terms of treatment and time of analysis (El Messaoudi
et al., 2016; Siravegna et al., 2017; Vidal et al., 2017).
Of note, plasma was obtained at different disease
stages and timing on treatment.
To better define the predictive nature of RAS
MAF levels, we performed a study in a homogeneous
group of patients with plasma samples collected sys-
tematically prior to the first or second treatment line,
to correlate RAS-mutant MAFs with clinical parame-
ters and to determine the impact of RAS-mutant
MAF on OS and progression-free survival (PFS) in
these disease settings. We also included an indepen-
dent cohort from the CAPRI-GOIM trial that was
assessed for clinical outcome based on plasma base-
line MAF (Ciardiello et al., 2014; Normanno et al.,
2017).
2. Materials and methods
2.1. Study design
This multicentric study included both retrospective
and prospective patients: Retrospective patients were
recruited from two Spanish hospitals (Vall d’Hebron
University Hospital and Catalan Institute of Oncology,
Duran I Reynals); prospective patients were recruited
from the Vall d’Hebron University Hospital only.
Additionally, an independent cohort of first-line
patients derived from the CAPRI-GOIM trial (regis-
tration number: 2009-014041-81) were also included.
The study was approved by the ethics committee of all
hospitals, and all patients signed written informed con-
sent. This study was conducted in accordance with the
Declaration of Helsinki and Good Clinical Practice
guidelines.
2.2. Patient characteristics
Patients from the TTD ULTRA clinical trial
(NCT01704703) were included. Of 110 mCRC plasma
samples screened, 62 (56%) were identified as RAS-
mutated by BEAMing in plasma. To obtain a homoge-
neous study population, we excluded patients with
liver-limited resected metastases, leaving 41 plasma
samples (37%) from 37 RAS-mutated patients with
nonresectable metastases for analysis (Fig. S1); of
them, 29 samples were prior to first-line therapy and
12 prior to second-line treatment (Table S1). Baseline
characteristics, number and location of metastasis, and
number and description of previous lines of therapy
are summarized in Table 1.
The CAPRI-GOIM trial, a nonprofit academic,
open-label, multicenter study, enrolled 340 mCRC
patients, KRAS exon-2 wild-type, according to local
pathology assessment, treated with FOLFOX plus
cetuximab vs FOLFOX at progression to first-line
FOLFIRI plus cetuximab (Eudract number: 2009-
014041-81) (Normanno et al., 2017). Of these, 33
patients were found mutated according to their plasma
sample and thus used in this study as an independent
validation set (Table S1) (Normanno et al., 2017). One
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patient was excluded for analysis due to lack of fol-
low-up data.
2.3. Sample collection
Blood samples (4 mL) were collected in CellSave
Preservative Tubes (Menarini-Silicon Biosystems,
Bologna, Italy), and plasma was isolated within 48 h.
For nontrial patients, 10 mL of blood was collected in
EDTA tubes and plasma was isolated within 1 h. A
two-step centrifugation was performed with blood ini-
tially centrifuged for 10 min at 1600 g at room tem-
perature. Supernatant was collected, avoiding the
buffy coat, and then centrifuged again for 10 min at
room temperature at 3000 g to remove remaining cells.
Plasma supernatant was transferred into a 1.5-mL tube
and stored at 80 °C until use.
2.4. DNA purification
Circulating free DNA (cfDNA) was performed with
the QIAamp Circulating Nucleic Acid Kit (QIAGEN,
Venlo, Netherlands) according to the manufacturer’s
instructions. DNA quality and concentration were
measured with a NanoDrop 1000 Spectrophotometer
(Thermo Scientific, Waltham, MA, USA).
2.5. Mutation detection by BEAMing technology
in ctDNA
RAS status was determined in plasma using BEAMing
(Sysmex Corporation, Kobe, Japan). The commercially
available, and previously validated (Grasselli et al., 2017),
CE-IVD BEAMing RAS plasma panel of mutations was
evaluated (Table S2). Plasma was processed as previously
described (Grasselli et al., 2017). Samples were considered
mutant according to a mutation rate threshold (0.02–
0.04%) based on the CE-IVD BEAMing RAS panel
assay, as per the manufacturer’s algorithm.
2.6. Statistics
Statistical analyses were performed using R 3.4.1, R
studio (v. 1.0.153, https://www.r-project.org/), and the
CRAN R survival package. Data are summarized by fre-
quency for categorical variables and by median and
range for continuous variables. PFS was defined as the
time from treatment start to disease progression or
death. OS was defined as the time from mCRC diag-
nosis to death from any cause or the last follow-up
visit. Response rate was assessed according to RECIST
1.1 (https://recist.eortc.org/).
Mutant allele fractions were calculated as the num-
ber of mutant beads divided by the total number of
beads analyzed, and all samples were analyzed blinded
to the study endpoints. Pearson’s correlation coeffi-
cients between MAF levels and selected clinical vari-
ables were determined. Clinical variables analyzed
included treatment line, primary site, number and loca-
tion of metastatic sites, best response, carcinoembry-
onic antigen (CEA) and CA 19-9 levels, number of
metastatic hepatic lesions, and hepatic lesion volume
(sum of the largest diameter of all hepatic lesions
[maximum 10], according to RECIST v1.1). Significance
was determined with nonparametric Kruskal–Wallis
tests; P-values < 0.05 were considered significant.
Hazard ratios (HR) and 95% confidence intervals
(CI) were calculated. Survival curves were estimated
using the Kaplan–Meier method. Log-rank tests,
including univariate and multivariate Cox proportional
hazards models, were performed for key endpoints.
2.7. MAF cutoff
The optimal MAF cutoff of 5.8% used in our cohort
was calculated based on our dataset using the R function
CUTP in the SURVMISC package (Contal and O’Quigley,
1999; Mandrekar et al., 2003). This function determines
the optimal cut point for a continuous variable in a
coxph or survfit model under the null hypothesis that
the chosen cutoff does not predict survival.
Table 1. Patient characteristics.
First-line
(N = 29; (%)
Second-line
(N = 12; %)
CAPRI-GOIM
(N = 33; %)
Gender
Male 19 (65) 7 (58) 16 (48)
Female 20 (35) 5 (42) 17 (52)
RAS-mutated
KRAS 12 16 (55) 7 (58) 19 (58)
KRAS 13 6 (21) 3 (25) 2 (6)
KRAS (others) 3 (10) 1 (8) 7 (21)
NRAS 12 1 (4) 0 2 (6)
NRAS 13 0 0 0
NRAS (others) 3 (10) 1 (8) 3 (9)
M1 metastatic sites
1 10 (35) 1 (8) 17 (52)
2 16 (55) 7 (58) 14 (42)
3+ 3 (10) 4 (33) 2 (6)
Primary site
Right 9 (31) 5 (42) 7 (21)
Left 12 (41) 0 16 (48)
Rectum 8 (28) 7 (58) 10 (31)
Treatment
FOLFOX 26 (89) 3 (25)
FOLFIRI 1 (4) 7 (58)
Antiangiogenics 9 (31) 5 (42)
Othersa 3 (10) 2 (17)
aFirst-line: 5-fluorouracil (5-FU) and capecitabine; Second-line:
irinotecan.
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3. Results
3.1. Correlation of MAF with clinical parameters
A total of 41 samples from 37 patients were ana-
lyzed, 29 prior to first-line and 12 prior to second-
line treatment. A wide range of plasma RAS MAFs
was seen for both the first- and second-line treatment
groups. Median MAF was 9.9% in the first-line
group (range: 0.014–51.5%) and 1.8% (range: 0.03–
52.4%) in the second-line group (Fig. 1A), although
not statistically significant. MAF distribution did not
correlate with tumor right/left sidedness or the num-
ber of metastatic sites (Fig. 1B,C) but, in contrast,
varied significantly according to the site of metastasis.
MAF median values were calculated according to
metastatic spread involving the liver, lung, lymph
nodes, or peritoneum (most patients had more than
one metastatic site). Median MAF was significantly
lower in patients with metastases in the peritoneum
compared to those with metastases in the liver
(P = 0.0003), lung (P = 0.044), or lymph nodes
(P = 0.025; Fig. 1D), although this observation is lim-
ited by sample size.
A multivariate Cox analysis showed that MAFs did
not significantly correlate with CA19-9 or CEA levels,
though a slight tendency to higher levels of CA19-9
was observed in samples with higher MAFs. CEA
levels were overall higher than reference values; how-
ever, no association was observed with MAFs
(Fig. S2, Table S3). Similarly, MAFs did not correlate
with the number of metastatic hepatic lesions or hep-
atic volume (Fig. S2).
3.2. Correlation of MAF with clinical outcomes
Overall, higher MAF values correlated with shorter
PFS (cor = 0.476; P = 0.009) and OS (cor = 0.506;
P = 0.005; Fig. S3E). We decided to set a cutoff MAF
value that split patients with better vs worse prognosis
in our cohort. This was done with the Cutpoint func-
tion (cutp) for a continuous variable in a Coxph or
Survfit model.
In the first-line setting, using an optimized MAF
cutoff of 5.8%, PFS was not significantly better in
samples with MAF < 5.8% (Fig. 2A); however, a
trend toward lower PFS was observed in samples with
a higher MAF. The difference in median PFS between
patients with RAS-mutant samples with MAF < 5.8%
(N = 10) and those with MAF ≥ 5.8% was
10.7 months vs 7.0 months with an HR of 2.2 (95%
CI: 0.94–7.20; P = 0.06).
Using the same optimized cutoff of 5.8%, samples
with MAF < 5.8% showed significantly better OS
(Fig. 2B). The difference in median OS between
patients with RAS-mutant samples having MAF
< 5.8% (N = 10) and those with MAF ≥ 5.8% was
26.7 months vs 11.4 months (HR: 3.5; 95% CI: 2.08–
43.1; P = 0.0006). RAS MAF was still an independent
variable for OS with a 1% cutoff, but at 10% cutoff,
HR was no longer significant (Fig. S3A–D).
In the second-line setting, the analyses show clearly
that patients with MAF < 5.8% have both longer PFS
and OS, with an HR of 6.6 and P = 0.00018 for both
variables, compared to those with MAF > 5.8%
(Fig. S4A,B). RAS MAF remained an independent
variable with cutoffs of 1% or 10% (Fig. S4C,F).
Mutant allele fractions were significantly higher in
patients whose outcome was progression disease (PD),
compared to those with partial response (PR; Fisher’s
test P = 0.002) or stable disease (SD; Fisher’s test
P = 0.014; Fig. 2C). One-way ANOVA test draws
identical conclusions (P = 0.007).
Univariate analyses in the first-line cohort including
different clinical factors such as tumor location, num-
ber of metastatic sites, gender, and CEA levels showed
plasma MAF was the only statistically significant
prognostic factor for OS. Multivariate Cox analysis
considering the previous biomarkers showed that
plasma RAS MAF was the strongest prognostic factor
for both PFS (HR: 3.74; 95% CI 1.01–13.92;
P = 0.049) and OS (HR: 2.73; 95% CI 2.35–182.53;
P = 0.006; Table 2).
Consistent with our results, in an independent
cohort at first-line treatment from the CAPRI-GOIM
trial, samples with MAF < 5.8% showed significantly
better OS (HR: 3.84; 95% CI 1.5–9.6; P = 0.004) and
longer PFS (HR: 2.5; 95% CI: 1.07–5.62; P = 0.033;
Fig. 3). Similar results were obtained when using a
cutoff of 10% (Fig. S5).
4. Discussion
This is the first clinical study that aims at specifically
assessing the prognostic potential of measuring RAS
MAFs in cfDNA in a homogenous group of mCRC
patients. Previously, we and others observed that
patients with lower OS tend to have a plasma RAS
MAF above 10% (El Messaoudi et al., 2016; Gras-
selli et al., 2017; Vidal et al., 2017). The present
study aimed to accurately define the impact of RAS
MAF in a homogenous cohort of mutated mCRC
patients, thereby excluding potential confounding fac-
tors, in the context of specific clinical parameters and
survival outcomes. We correlated RAS MAF with
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several clinical characteristics including previously
proposed prognostic biomarkers, such as laterality,
CEA, CA19.9, hepatic tumor volume, number of
metastatic sites, and previous lines of therapy, to gain
a better understanding of the biological basis of
plasma MAFs in mCRC patients. However, no linear
correlations were found with any of these parameters
—an outcome which warrants further research with
expanded cohorts.
To date, there is plausible evidence that the primary
tumor side might have prognostic value in mCRC
(Arnold et al., 2017; Petrelli et al., 2017). Our
multivariate analysis revealed that tumor sidedness
was not a prognostic factor in our cohort. This appar-
ent discordance with previous publications might be
accounted for by a bias concerning the study popula-
tions; our cohort is relatively small and included only
RAS-mutated mCRC samples, whereas other studies
were based on patients with RAS wild-type mCRC
(Arnold et al., 2017) or did not take RAS mutational
status into account (Petrelli et al., 2017).
While MAF distribution was independent of hepatic
tumor volume and the number of metastatic hepatic
lesions, the presence of metastases in the liver, lung, or
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Fig. 1. MAF distribution. Representation of MAF (%) distributions according to: (A) the two lines of treatment; (B) tumor laterality; (C)
number of metastatic lesions; and (D) metastatic site. Box plots show the interquartile range (IQR) with median, 25th and 75th percentile,
outliers, and P-values. Continued lines (in graph D) indicate the comparison between two variables. Statistically significant P-values are
marked with a (*). Samples are represented by light blue dots.
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lymph nodes was significantly associated with higher
MAFs. Although there is currently no clear explana-
tion for this phenomenon, our results are in line with
previous studies reporting that the site of metastatic
spread rather than the number of lesions has
prognostic value in mCRC (Riihim€aki et al., 2016;
Vidal et al., 2017; Yaeger et al., 2015).
Evaluation of best response to treatment showed
that patients with higher MAFs had PD or SD rather
than PR. Our study also indicates that patients with
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Fig. 2. PFS and OS analyses in first-line treatment. Survival curves are shown for samples with MAF < 5.8% (black line) and MAF> 5.8%
(red line) in terms of PFS (A) and OS (B) in the 1st line. HR and P-values are shown. (C) MAF distribution according to best response to
treatment.
Table 2. Multivariate analysis for first-line PFS and OS.
Risk factor
PFS OS
HR 95% CI P-value HR 95% CI P-value
Gender 2.37 0.77–7.38 0.135 1.20 0.33–4.38 0.778
Laterality 0.54 0.17–1.74 0.303 0.32 0.08–1.19 0.088
CEA 0.99 0.99–1.00 0.656 0.99 0.99–1.00 0.711
No. of hepatic lesions 1.04 0.32–3.37 0.947 1.05 0.30–3.70 0.935
Plasma MAF 3.74 1.01–13.92 0.049 2.73 2.35–182.53 0.006
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higher RAS MAFs do present with more resistant
tumors to conventional therapies. New or experimental
approaches should be considered for them.
In our multivariate statistical model, RAS MAF
did not correlate with either CEA or CA19-9, unlike
recent observation that elevated CA19-9 levels repre-
sented a strong prognostic marker (Rahbari et al.,
2017). However, we did observe that patients with
higher MAFs also tended to have higher levels of
both CA19-9 and CEA, though not reaching statisti-
cal significance.
The most striking finding of our analysis is that the
estimation of RAS MAF in liquid biopsies correlates
with predicting life expectancy in this mCRC popula-
tion. Our data provide evidence that baseline patients
with higher RAS MAFs in cfDNA tend to progress
after a shorter time and have significantly shorter OS.
An independent cohort from the CAPRI-GOIM trial
was analyzed, and plasma MAF at baseline resulted
statistically significant for prognosis in both OS and
PFS. An improved prognostic value in PFS was
observed in this first-line setting. A MAF cutoff was
selected, using the cutp algorithm, based on the ability
to better segregate outcomes in terms of PFS and OS
(5.8% MAF). Additional cutoffs of 1% and 10%
MAF used in previous publications (El Messaoudi
et al., 2016; Siravegna et al., 2017; Vidal et al., 2017)
were also evaluated, being 5.8% the one that overall
provided better prognostic value in our patient
cohorts. The sample size is indeed relatively small and
larger prospective studies to confirm our analyses and
further evaluate clinical parameters will be valuable.
5. Conclusion
Our data strongly support that RAS MAFs have inde-
pendent prognostic value for CRC survival and that,
along with tumor and patient characteristics, could
provide a useful noninvasive decision-making tool in
the first-line setting. After demonstrating the feasibility
for implementing liquid biopsies in routine care (Gras-
selli et al., 2017), we propose RAS MAFs as a novel
independent prognostic biomarker for mCRC.
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Fig. S1. Sample selection. Flowchart of selection steps
for the analysis population.
Fig. S2. Correlation analysis. Dot plots depicting the
correlation between MAF (%) and the following
parameters: CA19.9, CEA, hepatic volume and num-
ber of metastatic sites. Pearson correlation coefficient
(cor) and P-values are reported.
Fig. S3. PFS and OS analyses at different MAF cut-
offs in first-line treatment. Survival curves are shown
for samples with MAF < 1% (black line) and MAF
> 1% (red line) in terms of PFS (A) and OS (B), as
well as for samples with MAF < 10% (black line) and
MAF > 10% (red line) in terms of PFS (C) and OS
(D). HR and P-values are shown. Correlation between
PFS/OS and MAF is reported (E). Pearson correlation
coefficient (cor) and the P-value are reported.
Fig. S4. PFS and OS analyses in second-line treatment.
Survival curves are shown for samples with: (a) MAF
< 5.8% (black line) and MAF > 5.8% (red line) in
terms of PFS (A) and OS (B); (b) MAF < 1% (black
line) and MAF > 1% (red line) in terms of PFS (C)
and OS (D); (c) MAF < 10% (black line) and MAF
> 10% (red line) in terms of PFS (E) and OS (F). HR
and P-values are shown.
Fig. S5. PFS and OS analyses at different MAF cut-
offs in the validation cohort (CAPRI-GOIM trial).
Survival curves are shown for samples with MAF
< 1% (black line) and MAF > 1% (red line) in terms
of PFS (A) and OS (B), as well as for samples with
MAF < 10% (black line) and MAF > 10% (red line)
in terms of PFS (C) and OS (D). HR and P-values are
shown.
Table S1. Description of patients used in the study.
Table S2. RAS panel of mutations for BEAMing anal-
ysis.
Table S3. MAF tendency according to CA 19-9 and
CEA levels.
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